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Background:
• Anti-PD-1/L1 is associated with objective response rates (ORR) of 23-26%
in first line mTNBC, and 5-6% in later lines1,2
• Oral capecitabine (cape) is associated with ORR of 15-36% in metastatic
breast cancer (MBC)3
• Fixed-dose cape(1 week on, 1 week off) is active and well tolerated in
MBC, and maximizes tolerability/efficacy in mathematical models4,5
• Chemotherapy may induce immunogenic cell death, antigen
presentation, regulatory cell depletion, & PD-L1 upregulation6
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breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count 
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Results:
Hypothesis:
Pembrolizumab (pembro, anti-PD-1) plus fixed-dose capecitabine is safe,
and may enhance activity when combined for the treatment of mTNBC
Clinical Trial Objectives:
• Primary: To evaluate the tolerability of fixed-dose cape plus pembro
• Secondary: To evaluate the 3-month objective response rate (ORR) by
RECIST1.1 and immune-related RECIST1.1
Methods:
• Subjects with mTNBC with 0 or 1 prior systemic therapies were enrolled
to receive pembro (n=14, 200mg IV q21d) plus physician’s choice oral
cape (2,000mg BID, weekly 1 on/1 off) or paclitaxel (n=14)
• Sample size is based upon stage 1 of a Simon Phase II design with null
hypothesis of 25% ORR and alternative of 45% (80% power, 5% alpha)
1st/2nd line: 
mTNBC 
(ER/PR <1%, 
HER2/CEP17 
<2.0)
n=14 Weekly 
Paclitaxel + 
Pembro
n=14 Oral Cape 
+ Pembro
6 week 
primary 
endpoint: 
safety 
assessment 
12 week 
secondary 
endpoint:
objective 
response
Per physician's choice
Figure 1: Schematic & Cape Dose Reduction Levels
Dose level 0 -1 -2 -3 -4
Dose 2000mg BID 1500mg BID 1300mg BID 1150mg BID 1000mg BID
Efficacy Results:
• Pembro/cape was associated with 43% ORR (6 PR, 0 CR, Clopper-Pearson
95% CI: 18-71%), with an additional subject with durable SD (49+ wk)
• Mixed responses and new lesions (with ongoing response of target
lesions) were observed
Safety Results:
• 100% of patients (n=14/14) tolerated therapy (defined as >6 weeks
without discontinuation related to toxicity)
• Hand foot syndrome rates (71%, grade III-IV: 0%) were similar to cape
monotherapy (previous trials: 37-71%; grade III-IV: 8-26%)7-11
• Diarrhea rates (64%, grade III-IV: 14%) may be higher compared to cape
monotherapy (previous trials: 21-48%, grade III-IV: 4-13%)7-11 but was
managed effectively with dose reduction
Conclusion:
Pembro plus cape is safe
• Pembro plus fixed-dose cape was well tolerated, with no treatment
discontinuations related to toxicity
• Cape dose reductions were common to 1500mg BID
• Diarrhea may be increased with combination but is managed effectively
with dose reduction
• These data suggest that adjuvant cape can be safely co-administered
with pembro in ongoing neo-/adjuvant registrational TNBC studies
Pembrolizumab plus capecitabine is active
• The estimated 43% ORR is favorable relative to cape or pembro
monotherapy
• Sufficient responses were observed to warrant study expansion
according to the trial’s pre-specified Simon futility threshold
• Preceding cytotoxic chemotherapy may impair response to subsequent
immunotherapy in mTNBC
• A comparative assessment of the clinical and pharmacodynamic activity
of pembro/cape versus pembro/taxol is underway
Adverse Event Patients, n (%) Pembro attributed Cape attributed 
Fatigue 10 (71%) 4 (29%) 9 (64%)
Hand Foot Syndrome 10 (71%) 10 (71%)
Diarrhea 9 (64%) 9 (64%)
Cough 8 (57%) 2 (14%)
Dyspnea 8 (57%) 1 (7%)
Pain 8 (57%) 3 (21%)
Anemia 6 (43%) 3 (21%)
Anorexia 6 (43%) 2 (14%)
Hyponatremia 6 (43%) 1 (7%)
Nausea 6 (43%) 3 (21%)
Constipation 5 (36%) 2 (14%)
Headache 5 (36%)
Abdominal pain 4 (29%) 3 (21%)
Dry skin 4 (29%) 2 (14%)
Fever 4 (29%)
Hypokalemia 4 (29%) 3 (21%)
Lymphopenia 4 (29%) 2 (14%)
Vomiting 4 (29%) 2 (14%)
Wheezing 4 (29%)
Depression 3 (21%)
Dizziness 3 (21%)
Dry mouth 3 (21%) 1 (7%) 1 (7%)
Edema 3 (21%)
GERD 3 (21%) 2 (14%)
Hypothyroid 3 (21%) 3 (21%)
Pleural Effusion 3 (21%)
Table 2. Adverse events, all grades occurring in >15% study population
Adverse event Patients, n (%) Pembro attributed Cape attributed
Lymphopenia 3 (21) 2 (14)
Anemia 2 (14) 1 (7)
Diarrhea 2 (14) 2 (14)
Fatigue 1 (7) 1 (7)
Sepsis 1 (7) 1 (7)
Neutropenia 1 (7) 1 (7)
Hyperglycemia 1 (7) 1 (7)
Table 3. Grade III treatment-attributed adverse events (no grade IV)
Pt Study ID Week 4 Week 8 Week 12
1 2000mg BID 2000mg BID 1500mg BID
2 1500mg BID 1150mg BID
3 2000mg BID 2000mg BID 2000mg BID
4 2000mg BID 2000mg BID
5 2000mg BID 2000mg BID 2000mg BID
6 2000mg BID 2000mg BID 1500mg BID
7 2000mg BID 2000mg BID
8 2000mg BID 2000mg BID 1500mg BID
9 2000mg BID 2000mg BID 1500mg BID
10 2000mg BID 2000mg BID 1500mg BID
11 2000mg BID 2000mg BID 2000mg BID
12 2000mg BID 1300mg BID
13 2000mg BID 2000mg BID 1500mg BID
14 2000mg BID 1500mg BID
Crosshatch: treatment discontinued
Table 4. Cape dose reductions (7d on/7d off)
Characteristic No. (%) Characteristic No. (%) 
Age, y 62; range: 47-76 Neo-/adjuvant chemo
Ethnicity None 2 (14)
White 12 (86) ACT (+ Carbo in n=3) 9 (65)
Non-white 2 (14) TC 3 (21)
ECOG Time from neo-/adjuvant chemo
0 7 (50) ≤6mo from chemo 5 (42)
1 7 (50) >6mo from chemo 7 (58)
Line of therapy Liver involvement
First 12 (86) Yes 1 (7)
Second 2 (14) No 13 (93)
Dose Reductions:
• Dose reductions were required in 3/14 patients at wk 8, and 6/9 at wk 12
• Reason for dose reduction was: H/F syndrome (57%), diarrhea (29%)
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Table 1: Patient demographics
*2 pts not illustrated due to clinical progression and no scan available
Preliminary Correlates of Response:
• In previous anti-PD-1/L1 mTNBC studies, response rates diminish with
line of therapy, which could be related to chemotherapy-related
lymphopenia1,2
• Curative-intent chemotherapy is associated with prolonged contraction
of CD4 naïve cells
• In this dataset, we observe modest associations of response with CD4
naïve count, baseline ALC, and time from last chemo, suggesting that
iatrogenic immunosuppression may contribute to non-response in the
metastatic setting
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Figure 3. Preliminary Correlates of Response
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Figure 2: Tumor Response by RECIST 1.1
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